Syndromes of thrombosis and hypercoagulability: Congenital and acquired causes of thrombosis

Medical Clinics of North America

Volumn 82, Issue 3, 1998, Pages 409-458

  Bick, R L ^a   Kaplan, H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ESTROGEN;

CLINICAL FEATURE; CONGENITAL BLOOD CLOTTING DISORDER; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERCOAGULABILITY; MASS SCREENING; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; THROMBOSIS;

EID: 0031801933     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70004-3     Document Type: Article

References (313)

1. U. Abildgaard Purification of two progressive antithrombins of human plasma Scand J Clin Lab Invest 19 1967 190
2. U. Abildgaard Binding of thrombin to antithrombin III Scand J Clin Lab Invest 24 1969 23
3. U. Abildgaard M. Fagerhol O. Egeberg Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma Scand J Clin Lab Invest 26 1970 349
4. U. Abildgaard M.L. Larsen Assay of dermatan sulfate cofactor (heparin Cofactor II) activity in human plasma Thromb Res 35 1984 257
5. M.R. Aboud D.D. Ma A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation Br J Haematol 97 1997 798 803
6. L.D. Almer M. Pandolfi S. Osterlin The fibrinolytic system in patients with diabetes mellitus with special reference to diabetic retinopathy Ophthalmologica 170 1975 353
7. H. Al-Mondhiry D. Galanakis Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis J Lab Clin Med 110 1987 726
8. American Diagnostica Activated Protein C Assay 1984 American Diagnostic Newsletter Greenwich, CT
9. T. Anderson M. Larsen U. Abildgaard Low heparin cofactor II associated with abnormal crossed immunoelectrophoresis pattern in two Norwegian families Thromb Res 47 1987 243
10. N. Aoki M. Moroi Y. Sakata Abnormal plasminogen: A hereditary molecular abnormality found in a patient with recurrent thrombosis J Clin Invest 61 1978 1186
11. R.A. Asherson E.N. Harris Anticardiolipin antibodies: Clinical associations Postgrad Med J 62 1986 1081
12. T. Astrup Tissue activators of plasminogen Fed Proc 25 1966 42
13. A.S. Awidi M. Abu-Khalaf U. Herzallah Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan Am J Hematol 44 1993 95
14. W.F. Baker R.L. Bick Antiphospholipid antibodies in coronary artery disease Semin Thromb Hemost 20 1994 27
15. O. Ben-Tal A. Zivelin U. Seligsohn The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel Thromb Haemost 61 1989 50
16. L. Berg R. Edson J. Villablanca The effects of L-asparaginase on plasma levels of free protein S Am J Clin Pathol 93 1990 437
17. D. Bergqvist B. Lundblad Incidence of venous thromboembolism in medical and surgical patients Bergqvist D. Comerota A. Nicolaides A. Prevention of Venous Thromboembolism 1994 Med-Orion Press London 3
18. R.M. Bertina Hereditary protein S deficiency Haemostasis 15 1985 241
19. R.M. Bertina A.W. Broekmans van der Linden I.K. Protein C deficiency in a Dutch family with thrombotic disease Thromb Haemost 48 1982 1
20. Bertina R.M. Van der Linden I.K. L. Engesser Hereditary heparin cofactor-II deficiency and the risk of development of thrombosis Thromb Haemost 57 1987 196
21. R.M. Bertina Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 1993 64 67
22. R.L. Bick Clinical relevance of antithrombin III Semin Thromb Hemost 8 1982 276
23. R.L. Bick Antiphospholipid thrombosis syndromes: Etiology, pathophysiology, diagnosis and management Int J Hematol 65 1997 193
24. R.L. Bick The antiphospholipid thrombosis syndromes: Fact, fiction, confusion and controversy Am J Clin Pathol 100 1993 477
25. R.L. Bick The antiphospholipid thrombosis syndromes: Lupus anticoagulants, and anticardiolipin antibodies Adv Pathol Lab Med 8 1995 391
26. R.L. Bick Clinical hemostasis practice: The major impact of laboratory automation Semin Thromb Hemost 9 1983 139
27. R.L. Bick Disseminated intravascular coagulation Hematol Oncol Clin North Am 6 1992 1259
28. R.L. Bick Hemostasis in liver and renal disease Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice 1992 ASCP Press Chicago 175
29. R.L. Bick Syndromes associated with hyperfibrino(geno)lysis In: Disseminated Intravascular Coagulation and Related Syndromes 1983 CRC Press Boca Raton, FL 105
30. R.L. Bick Disseminated intravascular coagulation and related syndromes Bick R.L. Bennett J.M. Brynes R.K. Hematology: Clinical and Laboratory Practice 1993 CV Mosby St. Louis 1463
31. R.L. Bick Disseminated intravascular coagulation and related syndromes: A clinical review Semin Thromb Hemost 14 1988 299
32. R.L. Bick Hypercoagulability and thrombosis Bick R.L. Bennett J.M. Brynes R.K. Hematology: Clinical and Laboratory Practice 1993 CV Mosby St. Louis 1555
33. R.L. Bick Thrombolytic therapy. In: Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice 1992 ASCP Press Chicago 313
34. R.L. Bick Sticky platelet syndrome: A common cause of unexplained venous and arterial thrombosis—results of prevalence and treatment outcome Clin Appl Thromb Hemost 4 1998 1 5
35. R.L. Bick D. Ancypa The antiphospholipid and thrombosis syndromes: Clinical and laboratory correlates Clin Lab Med 15 1995 63
36. R.L. Bick W.F. Baker Anticardiolipin antibodies and thrombosis Hematol Oncol Clin North Am 6 1992 1287
37. R.L. Bick W.F. Baker The antiphospholipid and thrombosis syndromes Med Clin North Am 78 1994 667
38. R.L. Bick W.F. Baker Disseminated intravascular coagulation syndromes Hematol Pathol 6 1992 1
39. R.L. Bick M.D. Bick L.F. Fekete Antithrombin III patterns in disseminated intravascular coagulation Am J Clin Pathol 73 1980 577
40. R.L. Bick R.C. Bishop E. Shanbrom Fibrinolytic activity in acute myocardial infarction Am J Clin Pathol 57 1972 359
41. R.L. Bick M.L. Dukes W.L. Wilson Antithrombin III (AT-III) as a diagnostic aid in disseminated intravascular coagulation Thromb Res 10 1977 721
42. R.L. Bick J. Fareed Current status of thrombosis: A multidisciplinary medical issue and major American health problem—beyond the year 2000 Clin Appl Thromb Hemost 3 suppl 1 1997 1
43. R.L. Bick J. Fareed G. Squillaci Molecular markers of hemostatic processes: Implications in diagnostic and therapeutic management of thrombotic and hemorrhagic disorders Fed Proc 42 1983 4
44. R.L. Bick Y. Ismail W.F. Baker Coagulation abnormalities in patients with precocious coronary artery thrombosis and patients with failing coronary artery bypass grafting and percutaneous transcoronary angioplasty Semin Thromb Hemost 19 1993 411
45. R.L. Bick J. Jakway W.F. Baker Deep vein thrombosis: Prevalence of etiologic factors and results of management in 100 consecutive patients Semin Thromb Hemost 18 1992 267
46. R.L. Bick I. Kovac L. Fekete A new two-stage functional assay for antithrombin III (heparin co-factor): Clinical and laboratory evaluation Thromb Res 8 1976 745
47. R.L. Bick L. Kunkel Disseminated intravascular coagulation Int J Hematol 55 1992 1
48. R.L. Bick L. Kunkel Hypercoagulability and thrombosis Lab Med 23 1992 233
49. R.L. Bick L. Kunkel Hypercoagulability and thrombosis Lab Med 23 1992 233
50. R.L. Bick H.R. Laughlin B. Cohen Fetal wastage syndrome due to blood protein/platelet defects: Results of prevalence studies and treatment outcome with low-dose heparin and low-dose aspirin Clin Appl Thromb Hemost 1 1995 286
51. R.L. Bick B. McClain A clinical comparison of chromogenic, fluorometric and natural (fibrinogen) substrate assays for determination of antithrombin III Am J Clin Pathol 77 1982 238
52. R.L. Bick B.J. McClain A comparison of the Protopath and DuPont ACA antithrombin III assays in 149 patients with DIC, deep venous thrombosis, and hereditary thrombophilia Am J Clin Pathol 82 1984 371
53. R.L. Bick W.B. Thompson Fibrinolytic activity: Changes induced with oral contraceptives Obstet Gynecol 39 1972 213
54. A.G. Bird R. Lendrum R.A. Asherson Disseminated intravascular coagulation, antiphospholipid antibodies, and ischemic necrosis of extremities Ann Rheum Dis 46 1987 251
55. T.C. Bithell Hereditary dysfibrinogenemia Clin Chem 31 1985 509
56. W. Blaisdell Acquired and congential clotting syndromes World J Surg 14 1990 664
57. M. Blomback B. Blomback E.F. Mammen Fibrinogen Detroit: A molecular defect in the N-terminal disulfide knot of fibrinogen? Nature 218 1968 134
58. S.C. Bock J.F. Harris I. Balazs Assignment of the human antithrombin III structural gene to chromosome 1q23-q25 Cytogenet Cell Genet 39 1985 67 69
59. F.A. Bontempo The factor V Leiden mutation: Spectrum of thrombotic events and laboratory evaluation J Vasc Surg 2 1997 271 276
60. N. Bounameaux F. Duckert M. Walter The determination of antithrombin III: Comparison of six methods: Effect of oral contraceptive therapy Thromb Haemost 39 1978 607
61. E.J.W. Bowie J.H. Thompson C.A. Pascuzzi Thrombosis in systemic lupus erythematosus despite circulating anticoagulant J Lab Clin Med 62 1963 416
62. B. Brenner H. Mandel N. Lanir Activated protein C resistance can be associated with recurrent fetal loss Br J Haematol 97 1997 551
63. E. Briet L. Engesser E.J.P. Brommer Thrombophilia: Its causes and a rough estimate of its prevalence Thromb Haemost 58 1987 39
64. G.F. Briginshaw J.N. Shanberge Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X Thromb Res 4 1974 463
65. G.F. Briginshaw J.N. Shanberge Identification of two distinct heparin cofactors in human plasma: Separation and partial purification Arch Biochem Biophys 161 1974 683
66. K.M. Brinkhous H.P. Smith E.D. Warner Inhibition of blood clotting and unidentified substances which act in conjunction with heparin to prevent the conversion of prothrombin to thrombin Am J Physiol 125 1939 683
67. A.W. Broekmans Hereditary protein C deficiency Haemostasis 15 1985 233 240
68. A.W. Broekmans M.R. Bertina E.A. Loelinger Protein C and the development of skin necrosis during anticoagulant therapy [letter] Thromb Haemost 49 1983 255
69. Broekmans A.W. Van der Linden I.K. J.J. Veltkamp Prevalence of isolated protein C deficiency in patients with venous thromboembolic disease and in the population Thromb Haemost 50 1983 350
70. A.W. Broekmans J.J. Veltkamp R.M. Bertina Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families N Engl J Med 309 1983 340 344
71. M.A. Broekmans L. Engesser E. Briet Clinical manifestations of hereditary protein S deficiency Thromb Haemost 54 1985 57
72. Cancer Facts and Figures: 1996 1996 American Cancer Society Philadelphia
73. R. Candrina A. Goppini Antithrombin III deficiency Blood Rev 2 1988 239 250
74. R. Candrina A. Goppini A. Salvi Arterial thrombosis in antithrombin III deficiency Clin Lab Haematol 8 1986 267 268
75. J.F. Casella J.H. Lewis F.A. Bontempo Successful treatment of homozygous protein C deficiency by hepatic transplantation Lancet 1 1988 435 438
76. V. Chan T.K. Chan Antithrombin III in fresh and cultured human endothelial cells—a natural anticoagulant from the vascular endothelium Thromb Res 15 1979 209 213
77. S. Chandra N. Bang C. Marks Radiolabeled AT-III as a probe for the detection of activation of blood coagulation in vivo Thromb Res 9 1976 9
78. A. Chaunsumrit M.J. Manco-Johnson W.E. Hathaway Heparin cofactor II in adults and infants with thrombosis and DIC Am J Hematol 31 1989 109
79. D. Collen I. Juhan-Vague Fibrinolysis and atherosclerosis Semin Thromb Hemost 14 1988 180
80. P.C. Comp Laboratory evaluation of protein S status Semin Thromb Hemost 16 1990 177
81. P.C. Comp D. Doray D. Patton An abnormal plasma distribution of protein S occurs in functional protein S deficiency Blood 67 1986 504
82. P.C. Comp R. Nixon C.T. Esmon Determination of functional levels of protein C, an antithrombotic protein, using thrombin/thrombomodulin complex Blood 63 1984 15
83. P.C. Comp R.R. Nixon M.R. Cooper Familial protein S deficiency is associated with recurrent thrombosis J Clin Invest 74 1984 2082
84. P.C. Comp G.R. Thurnau J. Welsh Functional and immunological protein S levels are decreased during pregnancy Blood 68 1986 881
85. J. Conard B. Casenave M. Samama AT-III content and antithrombin activity in oestrogen-progesterone and progesterone-only treated women Thromb Res 18 1980 675
86. J. Conard M. Samama Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy Semin Thromb Hemost 13 1987 212
87. J. Conard M. Samama M. Horellou Congenital anti-thrombin III deficiency in 3 families (7 affected members) Thromb Haemost 42 1979 128
88. J. Conard M. Samama Y. Salomon Antithrombin III and the oestrogen content of combined oestro-progesterone contraceptives Lancet 2 1972 1148
89. M.G. Conlan W.D. Haire Low protein S in essential thrombocythemia with thrombosis Am J Hematol 32 1989 88
90. C.L. Conley R.C. Hartmann A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus J Clin Invest 31 1952 621
91. J. Corrigan Changes in the blood coagulation system associated with septicemia N Engl J Med 279 1968 851
92. A. D'Angelo S. Vigano-D'Angelo C.T. Essnon Acquired deficiencies of protein S: Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation J Clin Invest 81 1988 1445 1454
93. B. Dahlback New molecular insights into the genetics of thrombophilia: Resistance to activated protein C caused by Arg506 to Gin mutation in factor V as a pathogenic risk factor for venous thrombosis Thromb Haemost 74 1995 139 148
94. B. Dahlback M. Carlsson P.J. Svensson Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C Proc Natl Acad Sci U S A 90 1993 1004
95. A. D'Angelo M.S. Lockhart S.V. D'Angelo Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation released from platelets Blood 69 1987 231
96. M. Das S.F. Carroll Antithrombin III deficiency: An etiology of Budd-Chiari syndrome Surgery 97 1985 242 245
97. L. Dayan D. Donadio E. David Maladie thrombo-embolique familiale recidivante par deficit congenital en anti-thrombine III: Etude preliminaire de 3 observations Nouv Presse Med 7 1978 3229
98. de Fouw N.J. F. Haverkate R.M. Bertina The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro Blood 67 1986 1189
99. de Jong E. R.J. Porte E.A. Knot Disturbed fibrinolysis in patients with inflammatory bowel disease Gut 30 1989 188
100. G. Derue H. Englert E. Harris Fetal loss in systemic lupus: Association with anticardiolipin antibodies Br J Obstet Gynaecol 5 1985 207
101. Di Imperato C. A.G. Dettori Ipofibrinogenemia congenita con fibrinoastenia Helv Paediatr Acta 13 1958 380
102. R.G. DiScipio M.A. Hermodson S.G. Yates A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S Biochemistry 16 1977 698
103. R.G. DiScipio M.A. Hermodson S.G. Yates A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S Biochemistry 16 1977 698
104. M.J. Dufy P. O'Grady D. Devaney Urokinase-plasminogen activator, a marker for aggressive breast carcinomas Cancer 62 1988 531
105. J.M. Edelber M. Gonzales-Gronow S.V. Pizzo Lipoprotein(a) inhibition of plasminogen activation by tissue type plasminogen activator Thromb Res 57 1990 155
106. O. Egeberg Inherited antithrombin deficiency causing thrombophilia Thromb Diath Haemorrh 13 1965 516 530
107. A.M. Eng Cutaneous expressions of antiphospholipid syndromes Semin Thromb Hemost 20 1994 71
108. L. Engesser E.J.P. Brommer C. Kluft Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study of 203 patients with familial or sporadic venous thrombophilia Thromb Haemost 62 1989 673
109. L. Engesser A.W. Broekmans E. Briet Hereditary protein S deficiency: Clinical manifestations Ann Intern Med 106 1987 677 682
110. L. Engesser J. Koopman G. DeMunk Fibrinogen Nijmegen: Congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA Thromb Haemost 60 1988 113
111. H. Englert C. Hawkes M. Boey Dagos' disease: Association with anticardiolipin antibodies and the lupus anticoagulant BMJ 289 1984 576
112. C.T. Esmon Protein C: Biochemistry, physiology and clinical implications Blood 62 1983 1155
113. C.T. Esmon N.L. Esmon Protein C activation Semin Thromb Hemost 10 1984 122
114. M. Fagerhol U. Abildgaard Immunologic studies in human antithrombin III: Influence of age, sex, and use of oral contraceptives on serum concentration Scand J Haematol 7 1970 10
115. E.M. Faioni C. Razzari I. Martinelli Resistance to activated protein C in unselected patients with arterial and venous thrombosis Am J Hematol 55 1997 59
116. D.S. Fair B.R. Bahnak Human hepatoma cells secrete single chain factor X, prothrombin and antithrombin III Blood 64 1984 194 204
117. C.R. Falcon A.M. Hoffer R.R. Forastiero Clinical significance of various ELISA assays for detecting antiphospholipid antibodies Thromb Haemost 64 1990 21
118. J. Fareed H.L. Messmore E.W. Bermes New perspectives in coagulation testing Clin Chem 26 1980 1380
119. J. Fareed H.L. Messmore J.M. Walgena Laboratory evaluation of antithrombin III: A critical overview of currently available methods for antithrombin III measurements Semin Thromb Hemost 8 1982 288
120. J. Fareed H.L. Messmore J. Walenga Diagnostic efficacy of newer synthetic substrate methods for assessing coagulation variables: A critical overview Clin Chem 28 1983 2025
121. J.A. Fernandez T.M. Hackeng K. Kojima The carbohydrate moiety of factor V modulates inactivation by activated protein C Blood 89 1997 4348
122. G. Finazzi R. Caccia T. Barbui Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases Thromb Haemost 58 1987 1094
123. A.M. Fischer P. Cornu C. Sternberg Antithrombin III Alger: A new homozygous ATIII variant Thromb Haemost 55 1986 218 221
124. G. Frampton J.B. Winer J.S. Cameron Severe Guillain-Barré syndrome: An association with IgA anti-cardiolipin antibody in a series of 92 patients J Neuroimmunol 19 1988 133
125. R.B. Francis M.J. Patch A functional assay for protein C in human plasma Thromb Res 32 1983 605
126. K.D. Friedman R.A. Marlar J.G. Houston Warfarin-induced skin necrosis in a patient with protein S deficiency [abstr] Blood 68 1986 333a
127. J.E. Gardiner M.A. McGann C.W. Berridge Protein S as a cofactor for activated protein C in plasma and in the inactivation of purified factor VIII: C Circulation 70 1984 205
128. J.F. Guasch R.P. Lensen R.M. Bertina Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is “pseudo homozygous” for activated protein C resistance Thromb Haemost 77 1997 252
129. A.E. Gharavi E.N. Harris R.A. Asherson Anticardiolipin antibodies: Isotype distribution and phospholipid specificity Ann Rheum Dis 46 1987 1
130. A. Girolami The incidence of thrombotic manifestations in ATIII abnormalities Thromb Haemost 57 1987 123
131. C.L. Gladson I. Scharrer V. Hach The frequency of type 1 heterogenous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis Thromb Haemost 59 1988 18
132. K.H. Gladson J.H. Griffin V. Hach The incidence of protein C and protein S deficiency in 139 young thrombotic patients Thromb Haemost 59 1988 18
133. L.T. Goodnough H. Saito O.D. Ratnoff Thrombosis or myocardial infarction in congenital clotting factor abnormalities and thrombocytopenias: A report of 21 patients and a review of previously reported cases Medicine 62 1987 248
134. M. Gouault-Heilmann T. Gadwlha-Parente M. Levent Total and free protein S in nephrotic syndrome Thromb Res 49 1988 37
135. H. Gralnick H. Tan Acute promyelocytic leukemia: A model for understanding the role of the malignant cell in hemostasis Hum Pathol 5 1974 661
136. E. Grau A. Oliver J. Felez Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome Thromb Haemost 60 1988 137
137. J.H. Griffin Clinical studies on protein C Semin Thromb Hemost 10 1984 162
138. J.H. Griffin A. Bezeaud B. Evatt Functional and immunologic studies of protein C in thromboembolic disease Blood 62 1983 301a
139. J.H. Griffin B. Evatt T.S. Zimmerman Deficiency of Protein C in congenital thrombotic disease J Clin Invest 68 1981 1370
140. J.H. Griffin M.J. Heeb H.P. Schwarz Plasma protein S deficiency and thromboembolic disease Prog Hematol 15 1987 39
141. C.B. Grundy F. Thomas D. Millar Recurrent deletion in the human antithrombin III gene Blood 78 1991 1027 1032
142. E.N. Harris A.E. Gharavi M.L. Boey Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus Lancet 2 1983 1211
143. J.D. Hasday P.R. Bachwich J.P. Lynch Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoid Exp Lung Res 14 1988 261
144. D.K. Hasegawa B.J. Tyler J.R. Edson Thrombotic disease in three families with inherited plasminogen deficiency Blood 60 1982 213
145. W. Hathaway Clinical aspects of antithrombin III deficiency Semin Hematol 28 1991 19 23
146. M. Hatton L. Berry E. Regoecz Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta Thromb Res 13 1978 655
147. Heart and Stroke—1997 1996 American Heart Association National Headquarters Dallas, TX
148. U. Hedner I.M. Nilsson Urokinase inhibitors in serum in a clinical series Acta Med Scand 189 1971 185
149. M. Heeb D. Mosher J.H. Griffin Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation Blood 73 1989 455
150. H. Heijboer P.M. Brandjes H.R. Buller Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis N Engl J Med 323 1990 1512
151. M. Hellgren L. Javelin K. Hagnevik Antithrombin III concentrate as adjuvant in DIC treatment: A pilot study in 9 severely ill patients Thromb Res 35 1984 459
152. E.T. Hille R.G. Westendorp J.P. Vandenbroucke Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C) Blood 89 1997 1963
153. R.C. Hinton Neurological syndromes associated with antiphospholipid antibodies Semin Thromb Hemos 20 1994 46
154. M. Hook I. Bjork J. Hopwood Anticoagulant action of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin FEBS Lett 66 1976 90
155. P. Howie A. Mallinson C. Prentice Effect of combined oestrogen-progesterone oral contraceptives, oestrogen, and progesterone on antiplasmin and antithrombin activity Lancet 2 1970 1329
156. G.V.R. Hughes E.N. Harris A.E. Gharavi The anticardiolipin syndrome J Rheumatol 13 1986 486
157. I.A. Huisveld J.E.H. Hospers J.C.M. Meijers Oral contraceptives reduce total protein S, but not free protein S Thromb Res 45 1987 109
158. L. Intrator E. Oksenhendler L. Desforges Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura Br J Haematol 67 1988 269
159. I. Juhan-Vague C. Roul M.C. Alessi Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients—relationship with plasma insulin Thromb Haemost 61 1989 370
160. S. Kakkar P. Bentley P. Chan Oral contraceptives, AT-III, and deep vein thrombosis Thromb Haemost 42 1979 26
161. C.E. Kampe Clinical syndromes associated with lupus anticoagulants Semin Thromb Hemost 20 1994 16
162. A. Kanfer D. Kleinknecht M. Boyer Coagulation studies in 45 cases of the nephrotic syndrome without uremia Thromb Diath Haemorrh 24 1970 562
163. R. Kauffmann J. Veltkamp van Tilburg N. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome Am J Med 65 1978 607
164. M. Kazama C. Tahara Z. Suzki Abnormal plasminogen: A case of recurrent thrombosis Thromb Res 21 1981 517
165. A. Kendall R. Lohmann J. Dossetol Nephrotic syndrome: A hypercoagulable state Arch Intern Med 127 1971 1021
166. W. Kirschsteln S. Simianer C.E. Dempfle Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA) Thromb Haemost 62 1989 772
167. A. Kjaeldgaard B. Larsson Long-term treatment with combined oral contraceptives and cigarette smoking associated with impaired activity of tissue plasminogen activator Acta Obstet Gynecol Scand 65 1986 219
168. D. Kleinknecht G. Bobrie O. Meyer Recurrent thrombosis and renal vascular disease in a patient with lupus anticoagulant Nephrol Dial Transplant 4 1989 854
169. J. Ko P. Guaglianone M. Wolin Variation in the sensitivity of an activated thromboplasin time reagent to the lupus anticoagulant Am J Clin Pathol 99 1993 333
170. N. Kobayashi Y. Takeda Studies of the effects of estradiol, progesterone, cortisol, thrombophlebitis, and typhoid vaccine on synthesis and catabolism of antithrombin-III in the dog Thromb Haemost 37 1977 111
171. N.K. Kochenour D.W. Branch N.S. Rote A new postpartum syndrome associated with antiphospholipid antibodies Obstet Gynecol 69 1987 460
172. K. Kurachi G. Schmer M. Hermodson Inhibition of bovine factor IXa and factor Xa by anti-thrombin-III Biochemistry 15 1976 368
173. M.A. Laffan R. Manning The influence of factor VIII on measurement of activated protein C resistance Blood Coagul Fibrinolysis 7 1996 761
174. B. Lahiri R.D. Rosenberg R.O. Talamo Antithrombin-III: An inhibitor of human plasma kallikrein Fed Proc 33 1974 642
175. B. Lammle W. Wuillemin I. Huber Thromboembolism and bleeding tendency in congenital factor XII deficiency—a study on 74 subjects from 14 Swiss families Thromb Haemost 65 1991 117
176. D.A. Lane R. Caso Antithrombin: Structure, genomic organization, function and inherited deficiency Tuddenham E.G.D. Baillieres Clinical Haematology 1989 Bailliere Tindall London 961
177. K. Lechner H. Niessner E. Thaler Coagulation abnormalities in liver disease Semin Thromb Hemost 4 1977 40
178. K. Lechner E. Thaler N. Niessner Antithrombin-III-Mangel und Thromboseneigung Wein Klin Wochenschr 89 1977 215
179. S. Levine K. Welch The spectrum of neurologic disease associated with anticardiolipin antibodies Arch Neurol 44 1987 876
180. E. Li H. Orton R. Feinman The interaction of thrombin and heparin: Proflavine dye binding studies Biochemistry 13 1974 5012
181. H.R. Lijnen J. Soria C. Soria Dysfibrinogenemia (Fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation Thromb Haemostas 51 1984 108
182. S. Loizou J.D. McCrea A.C. Rudge Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results Clin Exp Immunol 62 1985 738
183. J. Malm R. Bennhagen L. Holmberg Plasma concentrations of C4b-binding protein and vitamin-K-dependent protein S in term and preterm infants: Low levels of protein S-C4b-binding protein complexes Br J Haematol 68 1988 445
184. E. Mammen Oral contraceptives and blood coagulation: A critical review Am J Obstet Gynecol 142 1982 781
185. E.F. Mammen Inhibitor abnormalities Semin Thromb Hemost 9 1983 42
186. E.F. Mammen Plasminogen abnormalities Semin Thromb Hemost 9 1983 50
187. E.F. Mammen Fibrinogen abnormalities Semin Thromb Hemostas 9 1983 1
188. E.F. Mammen Ten year's experience with the “sticky platelet syndrome.” Clin Appl Thromb Hemost 1 1995 66
189. E.F. Mammen M.I. Barnhart N.R. Selik “Sticky platelet syndrome”: A congenital platelet abnormality predisposing to thrombosis Folia Haematol 115 1988 361
190. E.F. Mammen W.R. Thomas W.H. Seegers Activation of purified prothrombin to autoprothrombin II (platelet cofactor II) or autoprothrombin II-A Thromb Diath Haemorrh 5 1960 218
191. C. Mannhalter M. Fischer P. Hopmeier Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis Fibrinolysis 1 1987 259
192. P. Mannucci A. Tripodi Laboratory screening of inherited thrombotic syndromes Thromb Haemost 57 1987 247
193. A.O. Mansfield Alterations in fibrinolysis associated with surgery and venous thrombosis Br J Surg 59 1972 754
194. E. Marciniak H.O. Wilson R.A. Marlar Neonatal purpura fulminans: A genetic disorder related to the absence of protein C in blood Blood 65 1985 15 20
195. J. Marcum F. Reilly R. Rosenberg The role of specific forms of heparan sulfate in regulating blood vessel wall function Prog Hemost Thromb 8 1986 185
196. R.A. Marlar J. Endres-Brooks Recurrent thromboembolic disease due to heterozygous protein C deficiency Thromb Haemost 50 1983 351
197. R.A. Marlar R.H. Sills R.R. Montgomery Protein C in commercial Factor IX (F IX) concentrations (CONC) and its use in the treatment of “homozygous” protein C deficiency Blood 62 1983 303
198. N. Marsh Fibrinolysis in disease. In: Fibrinolysis 1981 John Wiley & Sons New York 125
199. W.G. McGehee T.A. Klotz D.J. Epstein Coumarin-induced necrosis in a patient with familial protein C deficiency Blood 62 1983 304
200. E. McKay Immunochemical analysis of active and inactive antithrombin III Br J Haematol 46 1980 277
201. H.P. McNeil C.N. Chesterman S.A. Krilis Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics Br J Haematol 73 1989 506
202. E. Melissari V.V. Kakkar The effects of oestrogen administration on the plasma free protein S and C4b-binding protein Thromb Res 49 1988 489
203. D. Menache Replacement therapy in patients with hereditary antithrombin III deficiency Semin Hemat 28 1991 31 38
204. D. Menache J.P. O'Malley J.B. Schorr Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency Blood 75 1990 33 39
205. H.L. Messmore Natural inhibitors of the coagulation system Semin Thromb Hemost 8 1982 267
206. J.P. Miletich Laboratory diagnosis of protein C deficiency Semin Thromb Hemost 16 1990 169
207. M. Miller-Anderson H. Borg L.O. Anderson Purification of antithrombin III by affinity chromatography Thromb Res 5 1974 439
208. S. Moll T.L. Ortel Monitoring warfarin therapy in patients with lupus anticoagulants Ann Intern Med 127 1997 177
209. G. Muller-Berghaus Pathophysiology of generalized intravascular coagulation Semin Thromb Hemost 3 1977 209
210. H. Nagaswa B. Kim M. Steiner Inhibition of thrombin-neutralizing activity of antithrombin III by steroid hormones Thromb Haemost 47 1982 157
211. R.M. Nalbandian R.L. Henry R.L. Bick Thrombotic thrombocytopenic purpura: An extended editorial Semin Thromb Hemost 5 1979 216
212. I.M. Nilsson M. Pandolfi Fibrinolytic response of the vascular wall Thromb Diath Haemorrh 40 1970 231
213. I.M. Nilsson L.A. Tengborn A family with thrombosis associated with high level of tissue plasminbogen activator inhibitor Haemostasis 14 1984 24
214. O. Odegard U. Abildgaard Antithrombin-III: Critical review of assay methods: Significance of variations in health and disease Haemostasis 7 1978 127
215. O. Odegard M. Lie U. Abildgaard Heparin cofactor activity measured with an amidolytic method Thromb Res 6 1975 287
216. F.A. Ofosu F. Fernandez D. Gauther Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate Semin Thromb Hemost 11 1985 133
217. J.D. Oosting R.H. Derksen I.W.G. Bobbink Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism? Blood 81 1993 2618
218. S. Oppenheimer B. Hoffbrand Optic neuritis and myelopathy in systemic lupus erythematosus Can J Neurol Sci 13 1986 129
219. J. Owen Antithrombin III replacement therapy in pregnancy Semin Hematol 28 1991 46 52
220. P. Patracchinni V. Aiello P. Palazzi Subclonalization of the human protein C gene on chromosome 2q13-q14 Hum Genet 81 1989 191
221. M. Petaja V. Rasi G. Myllyla Familial hypofibrinolysis and venous thrombosis Br J Haematol 71 1989 393
222. C. Peterson R. Kelley B. Minard Antithrombin III: Comparison of functional and immunological assays Am J Clin Pathol 69 1978 500
223. R. Peterson P. Krull P. Finley Changes in antithrombin-III and plasminogen induced by oral contraceptives Am J Clin Pathol 53 1970 468
224. N.A. Pikaar M. Wedel van der Beek E.J. Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis and blood lipids Metab Clin Exp 36 1987 538
225. M. Pomerantz W. Owen A catalytic role for heparin: Evidence of a ternary complex of heparin cofactor, thrombin, and heparin Biochim Biophys Acta 535 1978 66
226. J.M. Pope C.L. Canny D.A. Bell Cerebral ischemic events associated with endocarditis, retinal vascular disease and lupus anticoagulant Am J Med 90 1991 299
227. G. Ramaswami A.N. Nicolaides The natural history of deep vein thrombosis Bergqvist D. Comerota A. Nocolaides A. Prevention of Venous Thromboembolism 1994 Med-Orion Press London 3
228. O.D. Ratnoff R.J. Busse R.P. Shean The demise of John Hageman N Engl J Med 279 1968 760 761
229. P. Reber M. Furlan A. Henschen Three abnormal fibrinogen variants with the same amino acid substitution (gamma-275 Arg-His): Fibrinogens Bergamo II, Essen and Perugia Thromb Haemost 56 1986 401
230. J.J. Reilly H.A. Chapman Association between alveolar macrophage plasminogen activator activity and indices of lung function in young cigarette smokers Am Rev Respir Dis 138 1988 1422
231. P.H. Reitsma S.R. Poort C.F. Allaart The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects Blood 78 1991 890 894
232. H. Reyes L. Dearing R.L. Bick Laboratory diagnosis of antiphospholipid syndromes Clin Lab Med 15 1995 85
233. P.M. Ridker J.P. Miletich C.H. Hennekens Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening JAMA 277 1997 1305 1307
234. B.W. Robinson Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease Thorax 43 1988 508
235. R.D. Rosenberg Action and interaction of antithrombin and heparin N Engl J Med 292 1975 146
236. F.R. Rosendaal Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women Blood 89 1997 2817
237. J. Rosing Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1997 233
238. M.H. Rosove P. Brewer A. Runge Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids Am J Hematol 32 1989 148
239. C. Rostoker M. Gouault-Heilmann M. Levent High level of protein C and protein S in nephrotic syndrome Nephron 46 1987 220
240. M. Rubenfire R.D. Blevins M.I. Barnhart Platelet hyperaggregability in patients with chest pain and angiographically normal coronary arteries Am J Cardio 57 1986 657
241. M. Saito I. Kumabashiri H. Jokaji The levels of protein C and protein S in patients with type II diabetes mellitus Thromb Res 52 1988 479
242. N. Sala W.G. Owen D. Collen A functional assay of protein C in human plasma Blood 63 1984 671
243. M.M. Samama D. Simon M.H. Horellou Diagnosis and clinical characteristics of inherited activated protein C resistance Haemostasis 26 suppl 4 1996 315 330
244. G. Sas Classification of antithrombin III deficiencies—has a new tower of Babel been built Thromb Haemost 60 1988 530 531
245. G. Sas Methodological considerations in antithrombin determination Acta Chir Scand 509 suppl 1982 97 99
246. G. Sas G. Blasko D. Banhegyi Abnormal antithrombin III (antithrombin-III “Budapest”) as a cause of familial thrombophilia Thromb Diath Haemorrh 32 1974 105
247. G. Sas I. Peto D. Banhegyi Heterogeneity of the “classical” antithrombin deficiency Thromb Haemost 43 1980 133
248. J.F. Schved C. Dupuy-Fons C. Biron A prospective epidemiological study on the occurrence of antiphospholipid antibody: The Montpellier Antiphospholipiod (MAP) Study Haemostasis 24 1994 175
249. R.S. Schwartz K.A. Bauer R.D. Rosenberg Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin Am J Med 87 suppl 3B 1989 53S 60S
250. H.P. Schwarz M. Fiscger P. Hopmeier Plasma protein S deficiency in familial thrombotic disease Blood 64 1984 1297
251. H.P. Schwarz M.J. Heeb J. Wencel-Drake Localization of protein S, an antithrombotic protein, in human platelets and megakaryocytes Blood 66 1985 353A
252. H.P. Schwarz G. Schernathaner J.H. Griffin Decreased plasma levels of protein S in well-controlled type I diabetes mellitus Thromb Haemost 57 1987 240
253. M.F. Scully V.V. Kakkar Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulfate Thromb Res 36 1984 187
254. W.H. Seegers E.R. Cole C.R. Harmison Neutralization of autoprothrombin-C activity with antithrombin Can J Biochem 42 1964 359
255. W.H. Seegers K.D. Miller E.B. Andrews Fundamental interaction and effect of storage, other adsorbents, and blood clotting in plasma antithrombin activity Am J Physiol 169 1952 700
256. W.H. Seegers H. Schroer M. Kagami Interactivation of purified autoprothrombin I with antithrombin Can J Biochem 42 1964 1425
257. U. Seligsohn A. Berger M. Abend Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn N Engl J Med 310 1984 559
258. B.S. Shi B.H. Chong C.N. Chesterman Beta-2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants Blood 81 1993 1255
259. P. Sie B. Boneu R. Bierme Arterial thrombosis and protein S deficiency Thromb Haemost 62 1989 1040
260. P. Sie D. Dupouy F. Dol Inactivation of heparin cofactor II by polymorphonuclear leukocytes Thromb Res 47 1987 657
261. P. Sie D. Dupouy J. Pichon Constitutional heparin cofactor II deficiency associated with recurrent thrombosis Lancet 2 1985 414
262. P. Sie F. Fernandez C. Caranobe Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate Thromb Res 35 1984 231
263. R.H. Sills J.R. Humbert R.R. Montgomery Clinical course and therapy of an infant with severe “homozygous” protein C deficiency Blood 62 1983 310
264. P. Simioni D. Scalia D. Tormene Intra-arterial thrombosis and homozygous factor V Leiden mutation Clin Appl Thromb Hemost 3 1997 215
265. H. Sinzinger J. Kaliman J. O'Grady Platelet lipoxygenase defect (Wien-Penzing defect) in two patients with myocardial infarction Am J Hematol 36 1991 202
266. J. Spero J. Lewis Y. Hasiba Disseminated intravascular coagulation: Findings in 346 patients Thromb Haemost 43 1980 28
267. N. Stead A.P. Kaplan R.D. Rosenberg Inhibition of activated factor XII by antithrombin-heparin cofactor J Biol Chem 251 1976 6481
268. M.B. Stemerman Vascular intimal components: Precursors of thrombosis Prog Hemost Thromb 2 1974 1
269. J. Stenflo Structure and function of protein C Semin Thromb Hemost 10 1984 109
270. J. Stenflo A new vitamin K-dependent protein: Purification from bovine plasma and preliminary characterization J Biol Chem 251 1976 355
271. J. Stenflo Structure and function of protein C Semin Thromb Hemost 10 1984 109
272. G. Sundkvist B. Lilja L.O. Almer Absent elevations in growth hormone, factor VIII related antigen, and plasminogen activator activity during exercise in diabetic patients resistant to retinopathy Diabetes Res 7 1988 25
273. T. Sveger Antithrombin III in adolescents Thromb Res 15 1979 885
274. P.J. Svensson B. Dahlback Novel mechanism for thrombosis characterized by poor anticoagulant response to activated protein C constitutes a major cause of thrombophilia Thromb Haemost 69 suppl 6 1993 999
275. P.J. Svensson B. Zoller B. Dahlback Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically Thromb Haemost 77 1997 335 332
276. M.D. Tabernero J.F. Tomas I. Alberca Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis Am J Hematol 36 1991 249
277. M.D. Tabernero A. Estelles V. Vicente Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism Thromb Res 56 1989 565
278. H. Takahashi K. Wada S. Hayashi Behavior of protein S during long-term oral anticoagulant therapy Thromb Res 51 1988 241
279. G. Tans J. Rosing Structural and functional characterization of factor XII Semin Thromb Hemost 13 1987 1 14
280. A. Teger-Nilsson Antithrombin in infancy and childhood Acta Paediatr Scand 64 1975 624
281. E. Thaler E. Balzar H. Kopsa Erworbener Antithrombin-III-Mangel bei Proteinurie Wien Klin Wochenschr 89 1977 65
282. E. Thaler E. Balzar N. Kopsa Acquired antithrombin III deficiency in patients with glomerular proteinuria Haemostasis 7 1978 257
283. E. Thaler K. Lechner Antithrombin III deficiency and thrombo-embolism Clin Haematol 10 1981 369
284. E. Thaler K. Lechner Antithrombin III deficiency and thrombolism Clin Haematol 10 1981 369 390
285. D.M. Tollefson Laboratory diagnosis of antithrombin and heparin cofactor II deficiency Semin Thromb Hemost 16 1990 162
286. D.M. Tollefson M.K. Blank Detection of a new heparin-dependent inhibitor of thrombin in human plasma J Clin Invest 68 1981 589
287. D.M. Tollefson D.W. Majerus M.K. Blank Heparin cofactor II: Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma J Biol Chem 257 1982 2162
288. D.M. Tollefson C.A. Pestka W.J. Monafo Activation of heparin cofactor II by dermatan sulfate J Biol Chem 258 1983 6713
289. C. Tomson C. Forbes C. Prentice Changes in blood coagulation and fibrinolysis in the nephrotic syndrome QJM 43 1974 399
290. P. Toulin J.F. Vitoux L. Capron Heparin cofactor II in patients with deep venous thrombosis under heparin and oral anticoagulant therapy Thromb Res 49 1988 479
291. T.H. Tran G.A. Marbet F. Duckart Association of hereditary heparin cofactor II deficiency with thrombosis Lancet 2 1985 413
292. A. Tripodi P.M. Mannucci A survey of inherited thrombotic syndromes in Italy Res Clin Lab 19 1989 67
293. J. Tullis K. Watanabe Platelet antithrombin deficiency: A new clinical entity Am J Med 65 1978 472
294. van der Meer J. Stoepman-van Dalen E. J. Jansen Anti-thrombin III deficiency in a Dutch family Am J Clin Pathol 26 1973 532
295. A.M. Vennerod K. Laake A.K. Soleberg Inactivation and binding of human plasma kallikrein by antithrombin III and heparin Thromb Res 9 1976 457
296. M. Verstraete The place of long-term stimulation of the endogenous fibrinolytic system: Present achievements and clinical perspectives Davidson J.F. Samama M.M. Desnoyers P.C. Progress in Chemical Fibrinolysis and Thrombolysis 1975 Raven Press New York 289
297. S. Vigano-D'Angelo A. D'Angelo C. Kaufman Protein S deficiency occurs in the nephrotic syndrome Ann Intern Med 107 1987 42
298. P. Vila M.C. Hernandez M.F. Lopez-Fernandez Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects Thromb Haemost 72 1994 209
299. H. Vinazzer Antithrombin III in shock and disseminated intravascular coagulation Clin Appl Thromb Hemost 1 1995 62
300. H. Vinazzar U. Pangraz Heparin cofactor II: A simple assay method and results of its clinical application Thromb Res 48 1987 153
301. P.P. Vomberg C. Breederveld Cerebral thromboembolism due to antithrombin III deficiency in two children Neuropediatrics 18 1987 42 44
302. von Kaulla E. von Kaulla K. Deficiency of antithrombin III activity with hereditary thrombosis tendency J Med 3 1972 349
303. F. Walker C. Esmon The molecular mechanism of heparin action: II. Separation of functionally different heparins by affinity chromatography Thromb Res 14 1979 219
304. F.J. Walker Protein S and the regulation of activated protein C Semin Thromb Hemost 10 1984 131
305. F.J. Walker Regulation of activated protein C by a new protein: A possible function for bovine protein S J Biol Chem 255 1980 5521
306. C.E. Weidmann D. Wallace J. Peter Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus J Rheumatol 15 1988 74
307. C. Weinstein M. Miller R. Axtens Livido reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus Arch Dermatol 123 1987 596
308. T. Wight Vessel proteoglycans and thrombogenesis Prog Hemost Thromb 5 1980 1
309. M. Wolf C. Boyer J. Lavergne A new variant of antithrombin III: A study of three related cases [abstr] Thromb Haemost 42 1979 186
310. P. Wolf H. Peter-Soyer P. Auer-Grumbach Widespread cutaneous necrosis in a patient with rheumatoid arthritis associated with anticardiolipin antibodies Arch Dermatol 127 1991 1739
311. E. Yin L. Eisenkramer J. Butler Heparin interaction with activated factor X and its inhibitor Adv Exp Med Biol 52 1974 239
312. B. Zoller A. Hillarp E. Berntorp Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis Annu Rev Med 48 1997 45 58
313. T. Zuck J. Bergin R. Perkins Antithrombin III and oestrogen content of oral contraceptives Lancet 1 1973 831